Table 1_Whole-genome microRNA sequencing analysis in patients with pulmonary hypertension.XLS

Pulmonary hypertension (PH) is a pathological disorder with multiple clinical manifestations that lead to cardiovascular and respiratory diseases in most patients. Recent studies have revealed that microRNAs (miRNAs) play important roles as upstream signaling molecules in several diseases, including PH. However, miRNAs that can be used as diagnostic or prognostic biomarkers for PH have not been identified. Thus, in this study, peripheral blood samples obtained from patients with PH and healthy individuals were subjected to genome-wide miRNA sequencing and transcriptome analysis. We screened 136 differentially expressed miRNAs in patients with PH and verified that four differentially expressed miRNAs, namely, hsa-miR-1304-3p, hsa-miR-490-3p, hsa-miR-11400, and hsa-miR-31-5p, could be used as clinical diagnostic biomarkers for pulmonary arterial hypertension. Our findings provide a basis for further in-depth investigations of the specific mechanisms of miRNAs in PH.

肺动脉高压（Pulmonary hypertension, PH）是一类具有多种临床表现的病理状态，多数患者会因此继发心血管及呼吸系统疾病。近期研究表明，微RNA（microRNAs, miRNAs）作为上游信号分子在包括PH在内的多种疾病中发挥关键调控作用。然而，目前尚未鉴定出可作为PH诊断或预后生物标志物的miRNAs。因此，本研究对PH患者与健康对照个体的外周血样本进行了全基因组miRNA测序与转录组分析。本研究共筛选出136个在PH患者中差异表达的miRNAs，并验证其中4个差异表达miRNAs——即hsa-miR-1304-3p、hsa-miR-490-3p、hsa-miR-11400及hsa-miR-31-5p——可作为动脉性肺动脉高压的临床诊断生物标志物。本研究结果为后续深入探究miRNAs在PH中的具体作用机制提供了重要理论依据。